Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Navlimetostat plus pembrolizumab and chemotherapy versus placebo plus pembrolizumab and chemotherapy in first-line MTAP-deleted metastatic non-small cell lung cancer
NL-OMON60334Phase 3Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Navlimetostat + pembrolizumab + chemotherapy with Placebo + pembrolizumab + chemotherapy (2 arms). Primary endpoints: Progression-free survival and Overall survival. Started Dec 2025; status: recruiting.
02
Drugs
navlimetostat
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON60334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60334.